Compugen Ltd. Aktie News

Pooled analysis supports the rationale for the ongoing MAIA-ovarian trial evaluating COM701 as maintenance therapy in the earlier setting of platinum sensitive ovarian cancer HOLON, Israel , Oct. 13, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today annou...

HOLON, Israel , Oct. 6, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery, powered by AI/ML today announced, that a trial in progress of the first in human clinical trial to assess the anti-IL18BP antibody, COM503 (GS-0321) in participants with advanced solid malignancies will b...

HOLON, ISRAEL , Sept. 8, 2025 /PRNewswire/ -- Compugen Ltd.

HOLON, Israel , Aug. 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today announced that management will participate in a fireside chat at the H.C.

Compugen is advancing its anti-PVRIG antibody COM701 in phase 1/2 as a maintenance therapy for relapsed platinum-sensitive ovarian cancer patients, with interim data expected in 2H 2026. Positive proof-of-concept in platinum-resistant ovarian cancer and strong partnerships with AstraZeneca and Gilead provide multiple value-creation opportunities and financial stability. Upcoming catalysts inclu...

Compugen Ltd. (NASDAQ:CGEN ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Anat Cohen-Dayag - CEO, President & Director David Silberman - Chief Financial Officer Eran Ophir - Chief Scientific Officer Michelle Mahler - Chief Medical Officer Yvonne Naughton - Head of Investor Relations & Corporate Communications Conference Call Participants Leland James Gershell ...

First patient dosed in MAIA-ovarian platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in July 2025 Pooled analysis from three previously reported Phase 1 trials of COM701 in platinum resistant ovarian cancer to be presented at ESMO 2025 Recruitment ongoing in Phase 1 trial of GS-0321 (COM503) a potential first-in-class anti-IL18BP antibody licensed ...

HOLON, Israel , July 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a pooled analysis of data from three Phase 1 trials evaluating COM701 as monotherapy and combination therapy in heavily pretreated platinum resi...